Background. The immune system has been shown to play an important role in gastrointestinal stromal tumor (GIST). The neutrophil-to-lymphocyte ratio (NLR) in blood is an easily assessable parameter of systemic inflammatory response. The aim of this study was to determine whether the NLR is prognostic in GIST. Methods. A total of 339 previously untreated patients with primary, localized GIST operated at our institution between 1995 and 2010 were identified from a prospectively collected sarcoma database. NLR was assessed preoperatively. Patients who received adjuvant imatinib treatment were excluded from the analysis (n = 64). Cox regression models were calculated and correlation analyses were performed. Results. On univariate analysis, NLR was associated with recurrence-free survival (RFS) (P = 0.003, hazard ratio 3.3, 95 % confidence interval 1.5-7.4). Patients with a low NLR had a 1-and 5-year RFS of 98 and 91 %, compared with 89 and 76 % in those with a high NLR. The median RFS was not reached. Positive correlations were found between NLR and mitotic rate (Pearson correlation coefficient [r] = 0.15, P = 0.03), and NLR and tumor size (r = 0.36, P = 0.0001). RFS in patients with a GIST [5 cm with low NLR was significantly longer compared to patients with high NLR (P = 0.002). Flow cytometry analysis of freshly obtained GISTs revealed that neutrophils constituted a minimal percentage of intratumoral immune cells. Conclusions. NLR is a surrogate for high-risk tumor features. Elevated blood NLR appears to represent systemic inflammation in patients with high-risk GIST.
1
Although GIST can occur throughout the gastrointestinal tract, the most common location is the stomach, accounting for 60-70 % of tumors. 2 The molecular alterations leading to the development of GIST have been well defined. 3, 4 Novel small molecule tyrosine kinase inhibitors were introduced in the treatment of GIST and have revolutionized the oncologic outcome of patients. The progress made in the management of this disease in the last 10 years may have been greater than in any other type of cancer. 5 In the era of adjuvant imatinib treatment, determining the risk for tumor recurrence has become increasingly important. Tumor specific parameters such as mitotic rate, size, and anatomical location of the primary lesion help in assessment of the biology of the disease. 6 More accurate risk stratification is possible by using nomograms, which permit quantifying the risk for recurrence after resection. 7, 8 The immune response is also an important factor in regard to outcome in GIST. Low secretion of interferon-c by stimulated peripheral natural killer (NK) cells from patients treated with imatinib and NK cell expression of the NKp30c isoform both correlate with worse outcome. 9, 10 Recently, we showed that imatinib inhibits tumor cell production of the immunosuppressive protein indoleamine 2,3-dioxygenase and subsequently increases the intratumoral ratio of CD8 T cells to T regulatory cells. 11 In addition, the profile of tumor infiltrating T lymphocytes correlates with imatinib sensitivity in human GISTs. Furthermore, in a mouse model of GIST, CTLA-4 inhibition was synergistic with imatinib therapy.
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Although intratumoral immune cells in GIST are prognostic, peripheral biomarkers would be a more useful clinical tool. The blood neutrophil-to-lymphocyte ratio (NLR) is an easily measured, reproducible, and inexpensive marker of systemic inflammation. High NLR has been associated with poor prognosis in several tumors, including renal cell, lung, ovarian, colorectal, and gastric cancer. [12] [13] [14] [15] [16] Elevated neutrophil counts in peripheral blood of GIST patients undergoing imatinib treatment were found to be predictive of poor treatment response and outcome. [17] [18] [19] [20] In this study, we sought to determine whether the blood NLR correlates with outcome in untreated, primary GIST.
METHODS

Patients
With approval of the Institutional Review Board and in accordance with Health Insurance Portability and Accountability Act regulations, a prospectively maintained sarcoma database was used. We identified 339 consecutive, previously untreated patients with a primary, localized GIST operated at Memorial Sloan-Kettering Cancer Center between 1995 and 2010. Patients who received adjuvant imatinib treatment (n = 64) were excluded from the survival analysis. Four patients had an incomplete set of blood values and were excluded as well. Extent of disease was preoperatively assessed by an abdominal/pelvic computed tomography (CT) or magnetic resonance imaging (MRI) and chest X-ray. All patients underwent surgical resection with curative intent. Recurrence was defined as evidence of disease relapse on CT or MRI and/or positron emission tomography.
Peripheral Blood Counts
Preoperative peripheral blood samples were collected within 10 days before surgery. No patient had clinical signs of infection at the time of blood sampling. Blood NLR was calculated as neutrophil count (number of neutrophils/lL) divided by lymphocyte count (number of lymphocytes/lL). High and low NLR were defined with respect to the sample median, which was 2.7. Similarly, the median values for the neutrophil and lymphocyte counts, the NLR, as well as the total white blood cell count were entered into a univariate and multivariate Cox regression model. Their role as markers for recurrence-free survival (RFS) was assessed and a potential correlation with established risk criteria was analyzed. 6 
Pathology
Tumor histology was established by a pathologist with expertise in sarcoma (C.R.A.). Immunohistochemical stains to determine the diagnosis of GIST were done on formalin-fixed, paraffin-embedded tumors using standard protocols, as previously described. 21 Tumor size, site, and mitotic rate (number of mitoses per 50 high-power fields [HPF]) were recorded. Mitotic rate was available in 261 cases (96 %) as a categorical value (\5/HPF or C5/HPF) and in 200 patients (74 %) as a continuous variable. Correlation analyses were performed with continuous variables. Survival analyses including mitotic rate, and tumor size and location were computed with categorical data.
Analysis of Neutrophils in Fresh Tumor Specimens
Twenty-two untreated, primary gastric GIST specimens were obtained freshly from the operating room from consenting patients under an IRB-approved protocol. Single cell suspensions were prepared by mincing tumor specimens and then digesting them in 12 mg/mL collagenase type II (Worthington Biochemicals) and 0.5 mg/mL DNAse I (Roche Diagnostics) for 30 min in a shaker at 37°C. Tumor suspensions were then filtered through a 100-lm nylon mesh filter and then a 40-lm filter. Matched peripheral blood was collected in heparinized tubes in 11 patients before the induction of anesthesia. Peripheral blood mononuclear cells (PBMCs) were obtained by density centrifugation over a Ficoll-Paque gradient (GE Healthcare). Cell suspensions from tumors and PBMCs were then stained with fluorochrome-conjugated antibodies for CD45 (clone 2D1; APC-Cy7), CD3 (clone SK7; PE-Cy7), CD19 (clone SJ25C1; PE-Cy7), CD56 (clone B159; PE-Cy7), CD11b (clone ICRF44; PE), CD14 (clone M/P9; APC), and CD16 (clone 3G8; AF-700), all from BD Biosciences. Fluorescence-activated cell sorting was performed with a FACSAria (BD Biosciences). Tumor neutrophils were defined as live CD45
? lineage -(CD3, 19, 56) CD11b
? CD14 -CD16 hi cells.
Statistical Analysis
Categorical data were compared by the v 2 test. Continuous values were analyzed by the Wilcoxon-MannWhitney U-test. Pairwise correlations were evaluated by the two-tailed Pearson-test. RFS was defined as the time from surgical resection to radiologic evidence of recurrence. Survival curves were computed by the KaplanMeier product limit method and compared by the log-rank test. Median values are reported with corresponding interquartile range (IQR). Univariate and multivariate Cox proportional hazard regression models were performed to identify associations with outcome variables. ANOVA test was used to compare differences between groups. Values are shown as hazard ratio (HR) with 95 % confidence interval (CI) and corresponding P value. A P value of \0.05 was considered statistically significant. The statistical analysis was performed with IBM SPSS 19 software (SPSS Inc., Chicago, IL).
RESULTS
Demographic and Tumor Profiles
The median age of the entire population at diagnosis was 65 years and half of the patients were female. The most common location was stomach (70 %), followed by small bowel (18 %), rectum (6 %), and other (5 %). The median mitotic rate was 3 mitoses/50 HPF (IQR 1-10) and the median tumor size was 5 cm (IQR 3-8.5). The median 2-and 5-year nomogram-predicted RFS in this series was 88 and 79 %, respectively.
19 Table 1 shows the baseline demographic, tumor, and treatment characteristics stratified by NLR in 335 GIST patients. Significantly more male (58 %) than female (42 %) patients had a high NLR.
NLR and Established Prognostic Criteria
A significant correlation was observed between blood NLR and mitotic rate (Pearson correlation coefficient (r) = 0.15, P = 0.03). An even stronger correlation was found between NLR and tumor size (r = 0.36, P = 0.0001; Fig. 1a) . Similarly, the blood neutrophil count correlated with tumor size (r = 0.34, P = 0.0001; Fig. 1b ). There was a tendency for reduced blood lymphocyte values in large GIST (r = -0.11, P = 0.08; Fig. 1c ). Blood neutrophil (r = 0.05, P = 0.45) and blood lymphocyte count (r = -0.07, P = 0.30) alone did not correlate with mitotic rate. There was a higher likelihood of having a high NLR in rectal GIST (Table 1) . Patients were classified into no risk of recurrence (n = 57), low (n = 127), moderate (n = 70), or high (n = 81) according to established criteria. 22 The median NLR in the high-risk group (4.7) was significantly different (P = 0.006) from the moderate-risk group (3.3) and the low-risk group (3.1).
RFS Analysis
With a median follow-up of 27 months (IQR 6-59), there were 8 recurrences (24 %) in the low NLR group and 24 recurrences (76 %) in the high NLR group. On univariate analysis, NLR (HR 3.3) and neutrophil count (HR 2.1), but not lymphocyte count and white blood cell, were associated with RFS (Table 2) . NLR was not independent from the nomogram-predicted outcome (P = 0.12) or Miettinen risk category (P = 0.11) in a multivariate model. 7, 22 Patients with a high NLR had a shorter RFS (Fig. 2 , P = 0.002). The 1-and 5-year RFS in the high NLR group was 89 and 76 %, compared to 98 and 91 % in the low group, and the medians were not reached. Because we found a strong correlation between NLR and tumor size, we analyzed RFS by these two variables (Fig. 3) . Patients with tumors greater than 5 cm in size had a 1-and 5-year RFS of 94 and 81 % if the NLR was low, but 80 and 57 % if the NLR was high (P = 0.02).
Intratumoral Neutrophils
We first analyzed intratumoral neutrophils from 14 freshly obtained GIST specimens and matched blood samples by flow cytometry. Neutrophils were defined as live CD45
? lineage -(CD3, 19, 56) CD11b ? CD14 -CD16 hi cells. Although there was the expected number of neutrophils in peripheral blood, the neutrophils comprised a low percentage of the immune (CD45 ? ) cells within the tumor (Fig. 4) . These results were confirmed in 8 other untreated primary GISTs (data not shown).
DISCUSSION
There is growing evidence that the immune system is important in untreated, primary GIST. We previously reported that GISTs induce an intratumoral T cell immune response. 11 However, the baseline ratio of CD8 T cells to T regulatory cells was relatively unfavorable and the tumor cells expressed an immunosuppressive enzyme (indoleamine 2,3-dioxygenase), the inhibition of which played a key role in the efficacy of imatinib treatment. 11 Thus, there appears to be local immune suppression in GIST. Nevertheless, tumor-restricted antigens in GIST have been identified as potential immunological targets and were shown to correlate with prognosis. 23, 24 We now have discovered that an increased level of peripheral blood neutrophil cells correlates with tumor biology. High NLR was associated with high-risk tumor features. Thus, highrisk GISTs induce a systemic inflammatory response.
Despite decades of investigation, the interaction between cancer cells and neutrophils is poorly understood. High neutrophil counts have been associated with poor survival in patients with metastatic melanoma, metastatic renal cell, breast, and advanced non-small cell lung cancer among others. [25] [26] [27] [28] [29] [30] On the other hand, multiple older studies have advocated a role of direct or antibodydependent killing of tumor cells by neutrophils, with one of the oldest reports, by William Coley, originating from our institution. 31, 32 He observed that patients with febrile streptococcal infection within an ulcerated tumor had a better prognosis than patients with uninfected tumors. Since Coley's initial report, knowledge about regulatory mechanisms in cellular immunity has increased vastly. However, cancer therapy utilizing a neutrophil-mediated approach has not yet been established.
In this study, the number of circulating blood lymphocytes was not associated with either RFS, or any of the established prognostic criteria (size, location, and mitotic rate). However, a nonsignificant correlation for reduced numbers of blood lymphocytes was seen in patients with large GISTs. In solid tumors, the pretreatment blood lymphocyte value has not been associated with prognosis. Thus, the NLR in untreated, primary GIST seems to be mainly determined by the neutrophil count. In contrast to tumor infiltrating lymphocytes, we found that tumor infiltrating neutrophils are unlikely to be important in untreated GIST because analysis by flow cytometry indicated there were few of them. It remains unclear why neutrophils are high in peripheral blood of patients with high-risk tumors but are virtually absent in tumor tissue.
There are several limitations of the present study. We excluded patients treated with adjuvant imatinib and therefore eliminated many high-risk patients, which reduced the number of recurrences. Because adjuvant imatinib significantly prolongs RFS and reduces the risk of recurrence, we could not include such patients. 33 However, our data in primary GIST are consistent with the fact that the baseline granulocyte count correlated to poor outcome in the European and North American Phase III trials of imatinib in advanced GIST. 17, 18 In conclusion, we observed a systemic inflammatory response in untreated patients with a high-risk GIST. NLR is a surrogate for poor prognosis in GIST and may represent a valuable parameter for predicting tumor biology from peripheral blood. The mechanism of neutrophilia in highrisk GIST remains unclear and requires further study.
